(Q37812125)

23 August 2017

title

Human influenza vaccines and assessment of immunogenicity (English)

1 reference

23 August 2017

1 reference

Zichria Zakay-Rones

1

1 reference

23 August 2017

publication date

1 December 2010

1 reference

Expert Review of Vaccines

23 August 2017

published in

1 reference

23 August 2017

volume

9

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1423-1439

1 reference

Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Seasonal inactivated influenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

The influence of sequential annual vaccination and of DHEA administration on the efficacy of the immune response to influenza vaccine in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Mapping the antigenic and genetic evolution of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

2008-2009 Influenza update: a better vaccine match

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Selection of influenza vaccine strains and developing pandemic vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Protective Effect of Vaccination Against Induced Influenza A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Clinical and serological response in humans following immunization with Gripax influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Live attenuated versus inactivated influenza vaccine in infants and young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Antibody quantity versus quality after influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

On the relationship between mean antibody level, seroprotection and clinical protection from influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Prediction of mutation trend in hemagglutinins and neuraminidases from influenza A viruses by means of cross-impact analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Influenza virus neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

An inhibition test for identifying the neuraminidase antigen on influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

The role of hemagglutinin in the inhibition of neuraminidase activity of influenza virus by concanavalin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Inhibition of influenza viral neuraminidase activity by collectins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

A molecular mechanism for the low‐pH stability of sialidase activity of influenza A virus N2 neuraminidases1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Variation in the divalent cation requirements of influenza A virus N1 neuraminidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Plaque Formation by Influenza Viruses in the Presence of Trypsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

A sensitive plaque inhibition technique for assay of antibodies to influenza virus: Use to detect previous antigenic priming with influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997-98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Cytotoxic T-cell immunity to influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Human memory CTL response specific for influenza A virus is broad and multispecific

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Purified influenza virus nucleoprotein protects mice from lethal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Cellular response in humans following vaccination with Gripax influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Local and peripheral cell-mediated immune response to influenza virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

A universal influenza A vaccine based on the extracellular domain of the M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

A "universal" human influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Universal influenza A vaccine: optimization of M2-based constructs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

The NB Protein of Influenza B Virus Is Not Necessary for Virus Replication In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Novel generations of influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Influenza B virus BM2 protein is an oligomeric integral membrane protein expressed at the cell surface.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Protection against influenza B virus infection by immunization with DNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Generation of influenza A viruses entirely from cloned cDNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Production of a novel influenza vaccine using insect cells: protection against drifted strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

21 January 2018

Influenza DNA vaccines

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

A launch vector for the production of vaccine antigens in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

A plant-produced influenza subunit vaccine protects ferrets against virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Synthetic Recombinant Vaccines against Viral Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Aluminium compounds for use in vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Vaccine adjuvants alter TCR-based selection thresholds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Engineering liposomes for drug delivery: progress and problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Immunostimulating reconstituted influenza virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Intradermal vaccine delivery: will new delivery systems transform vaccine administration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Influenza virus infections in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

An influenza A(H3) reassortant was epidemic in Australia and New Zealand in 2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

Emerging vaccines for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.144

21 January 2018

Identifiers

DOI

10.1586/ERV.10.144

1 reference

23 August 2017

1 reference